

SUPPLEMENTARY DATA

Supplementary Table 1. Clinical characteristics of study population included in or excluded from this study

	Included subjects	Excluded subjects	P value
	(n=228,778)	(n=88,101)	
Age, years	63.2±8.7	62.7±9.2	<0.001
Men, n (%)	89,877 (39.3)	36,123 (41.0)	<0.001
Body mass index, kg/m ²	23.0±3.3	23.1±3.3	<0.001
Current smoker, n (%)	31,777 (13.9)	14,530 (16.5)	<0.001
Daily drinker, n (%)	51,508 (22.5)	21,006 (23.8)	<0.001
Anti-hypertensive drugs, n (%)	61,668 (27.0)	23,186 (26.3)	<0.001
eGFR, mL/min/1.73m ²	75.5±16.0	77.0±17.1	<0.001
eGFR<60 mL/min/1.73m ² , n (%)	30,272 (13.2)	10,929 (12.4)	<0.001
Proteinuria (≥1+), n (%)	12,090 (5.3)	3,768 (4.3)	<0.001
BP parameters			
Systolic BP, mmHg	128.4±17.4	128.5±17.2	0.09
Diastolic BP, mmHg	76.1±10.7	76.1±10.9	0.20
Pulse pressure, mmHg	52.3±12.6	52.5±12.7	0.001

Data are expressed as the means ± SD or percentage. eGFR was calculated as follows: $194 \times \text{age (years)}^{-0.287} \times \text{serum creatinine (mg/dl)}^{-1.094}$ (if women $\times 0.739$). eGFR indicates the estimated glomerular filtration rate; BP, blood pressure.

SUPPLEMENTARY DATA

Supplementary Table 2. Clinical characteristics and metabolic or BP parameters according to the quintile of pulse pressure (n=228,778)

	1 st	2 nd	3 rd	4 th	5 th	P value
	(n=53,290)	(n=39,238)	(n=48,869)	(n=46,870)	(n=40,511)	
Age, years	59.1±10.0	61.5±9.3	63.6±8.4	65.4±7.3	67.2±6.1	<0.001
Men, n (%)	20,802 (39.0)	15,720 (40.1)	19,440 (39.8)	18,336 (39.1)	15,579 (38.5)	<0.001
Body mass index, kg/m ²	22.4±3.3	22.8±3.2	23.2±3.3	23.4±3.3	23.6±3.4	<0.001
Current smoker, n (%)	8,969 (16.8)	5,922 (15.1)	6,447 (13.2)	5,718 (12.2)	4,721 (11.7)	<0.001
Daily drinker, n (%)	11,092 (20.8)	8,715 (22.2)	11,118 (22.8)	10,886 (23.2)	9,697 (23.9)	<0.001
Diabetes, n (%)	4,220 (7.9)	3,793 (9.7)	5,734 (11.7)	6,567 (14.0)	7,599 (18.8)	<0.001
Pre-diabetes, n (%)	21,208 (39.8)	16,993 (43.3)	21,939 (44.9)	21,498 (45.9)	18,576 (45.9)	<0.001
eGFR, mL/min/1.73m ²	76.6±15.8	76.1±15.8	75.4±15.9	75.0±16.2	74.2±16.5	<0.001
Proteinuria (≥1+), n (%)	1,985 (3.7)	1,675 (4.3)	2,423 (5.0)	2,632 (5.6)	3,375 (8.3)	<0.001
Anti-hypertensive drugs, n (%)	6,613 (12.4)	7,728 (19.7)	13,314 (27.2)	16,138 (34.4)	17,875 (44.1)	<0.001
Anti-hyperlipidemic drugs, n (%)	5,761 (10.8)	5,394 (13.7)	8,117 (16.6)	8,864 (18.9)	8,360 (20.6)	<0.001
Anti-hyperglycemic drugs, n (%)	1,382 (2.6)	1,287 (3.3)	2,157 (4.4)	2,681 (5.7)	3,401 (8.4)	<0.001
Glucose and lipid parameters						
*Fasting glucose, mg/dl	91.0	92.0	93.0	94.0	96.0	<0.001
	(86.0-98.0)	(87.0-100.0)	(87.0-101.0)	(88.0-103.0)	(89.0-107.0)	
*Hemoglobin Alc, %	5.1	5.2	5.2	5.2	5.3	<0.001
	(4.9-5.4)	(5.0-5.4)	(5.0-5.5)	(5.0-5.5)	(5.0-5.6)	
*Triglycerides, mg/dl	91.0	96.0	98.0	100.0	103.0	<0.001
	(67.0-130.0)	(70.0-135.0)	(72.0-138.0)	(73.0-141.0)	(75.0-145.0)	
*Low-density lipoprotein, mg/dl	124.0	125.0	126.0	125.0	126.0	<0.001
	(105.0-145.0)	(106.0-146.0)	(107.0-146.0)	(106.0-146.0)	(107.0-146.0)	
*High-density lipoprotein, mg/dl	62.0	62.0	61.0	61.0	60.0	<0.001
	(52.0-74.0)	(51.0-73.0)	(51.0-73.0)	(51.0-72.0)	(51.0-72.0)	
BP parameters						
Systolic BP, mmHg	111.2±11.5	121.4±10.5	128.1±10.2	135.6±10.5	149.8±14.7	<0.001
Diastolic BP, mmHg	74.0±10.5	75.6±10.3	76.7±10.0	76.9±10.3	77.7±11.8	<0.001
Pulse pressure, mmHg	37.2±4.5	45.9±1.7	51.5±1.7	58.7±2.2	72.0±8.5	<0.001

Data are expressed as the means ± SD or percentage, and variables with skewed distribution (asterisks) are expressed as median (interquartile range). P values were obtained by ANOVA or chi-squared test. eGFR indicates estimated glomerular filtration rate; BP, blood pressure.